COVID-19, SARS-CoV 2, SARS-CoV Infection
Conditions
Keywords
COVID-19 convalescent plasma, convalescent plasma transfusion
Brief summary
This is an expanded access program providing COVID-19 convalescent plasma to patients hospitalized with severely or life-threateningly ill COVID-19.
Detailed description
This expanded access program provides hospitalized patients who are severely or life-threateningly ill with COVID-19 access to investigational COVID-19 convalescent plasma (CCP). A clinical team comprised of Infectious Disease specialists, Pulmonary/Critical Care specialists and Hospitalists identify appropriate patients in accordance with FDA recommendations for patient eligibility and the daily availability of ABO-compatible CCP. CCP is obtained through New York Blood Center and American Red Cross in coordination with the University Hospital Blood Bank. Safety outcomes include monitoring for transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO) and any allergic reactions.Patients admitted to our institution prior to the availability of CCP will be separately reviewed.
Interventions
BIOLOGICALCOVID-19 Convalescent Plasma
COVID-19 Convalescent Plasma from recovered COVID-19 patients transfusion into severely or life-threateningly ill COVID-19 infected patients
Sponsors
University Hospital - Newark, NJ
Rutgers, The State University of New Jersey
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Laboratory confirmed COVID-19. 2. Severe or life-threatening COVID-19. a) Severe disease is defined as one or more of the following: i) dyspnea, ii) respiratory frequency ≥ 30/min, iii) blood oxygen saturation ≤ 93%, iv) partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300, and/or v) lung infiltrates \> 50% within 24 to 48 hours b) Life-threatening disease is defined as one or more of the following: i) respiratory failure, ii) septic shock, and/or iii) multiple organ dysfunction or failure
Exclusion criteria
1. Contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products) 2. Severe multi-organ failure and hemodynamic instability requiring high doses of pressor agents 3. Other documented uncontrolled infection 4. Severe DIC needing factor replacement, FFP, cryoprecipitate 5. Acute renal failure requiring dialysis 6. Active intracranial bleeding 7. Clinically significant myocardial ischemia
Countries
United States
Outcome results
None listed